[go: up one dir, main page]

WO2003039480A3 - Method of treating disorder related to high cholesterol concentration - Google Patents

Method of treating disorder related to high cholesterol concentration Download PDF

Info

Publication number
WO2003039480A3
WO2003039480A3 PCT/US2002/035900 US0235900W WO03039480A3 WO 2003039480 A3 WO2003039480 A3 WO 2003039480A3 US 0235900 W US0235900 W US 0235900W WO 03039480 A3 WO03039480 A3 WO 03039480A3
Authority
WO
WIPO (PCT)
Prior art keywords
high cholesterol
treating
cholesterol concentration
disorder related
treating disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/035900
Other languages
French (fr)
Other versions
WO2003039480A2 (en
Inventor
Shutsung Liao
Ching Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Priority to CA002466033A priority Critical patent/CA2466033A1/en
Priority to AU2002356919A priority patent/AU2002356919B2/en
Priority to EP02802882A priority patent/EP1450816A4/en
Priority to JP2003541772A priority patent/JP2005508368A/en
Publication of WO2003039480A2 publication Critical patent/WO2003039480A2/en
Publication of WO2003039480A3 publication Critical patent/WO2003039480A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I). Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.
PCT/US2002/035900 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration Ceased WO2003039480A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002466033A CA2466033A1 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration
AU2002356919A AU2002356919B2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration
EP02802882A EP1450816A4 (en) 2001-11-08 2002-11-08 METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION
JP2003541772A JP2005508368A (en) 2001-11-08 2002-11-08 Methods for treating diseases associated with high cholesterol levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
US60/348,020 2001-11-08

Publications (2)

Publication Number Publication Date
WO2003039480A2 WO2003039480A2 (en) 2003-05-15
WO2003039480A3 true WO2003039480A3 (en) 2003-06-19

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035900 Ceased WO2003039480A2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Country Status (5)

Country Link
EP (1) EP1450816A4 (en)
JP (1) JP2005508368A (en)
CA (1) CA2466033A1 (en)
TW (1) TW200300078A (en)
WO (1) WO2003039480A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CA2585623C (en) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
KR20090081020A (en) 2006-11-13 2009-07-27 노파르티스 아게 Substituted Pyrazole and Triazole Compounds as PSP Inhibitors
JP2013500986A (en) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ Liver X receptor agonist
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
HUE062616T2 (en) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroactive steroids, preparations and their applications
RU2684103C2 (en) 2013-03-13 2019-04-04 Сейдж Терапьютикс, Инк. Neuroactive steroids and methods for use thereof
CN119269811A (en) * 2013-03-13 2025-01-07 萨奇治疗股份有限公司 Neuroactive steroids, compositions, and uses thereof
JP2016193835A (en) * 2013-09-04 2016-11-17 学校法人常翔学園 Nuclear receptor liver X receptor agonist
MX377151B (en) 2013-12-24 2025-03-07 Us Dept Veterans Affairs USES OF OXYGENATED CHOLESTEROL SULFATES (SOC).
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4609866A3 (en) 2015-07-06 2025-10-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (en) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR APPLICATION
RU2754130C2 (en) 2016-04-01 2021-08-27 Сейдж Терапьютикс, Инк. Oxysterols and their application methods
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3031224A1 (en) 2016-08-02 2018-02-08 Shunlin Ren Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
MA46351A (en) 2016-09-30 2021-06-02 Sage Therapeutics Inc C7 SUBSTITUTED OXYSTEROLS AND PROCESSES AS NMDA MODULATORS
TWI836485B (en) 2016-10-18 2024-03-21 美商賽吉醫療公司 Oxysterols and methods of use thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
EP0562849A2 (en) * 1992-03-27 1993-09-29 Eli Lilly And Company Steroid derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (en) * 1972-12-06 1974-07-24
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (en) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd Fluorine derivative of cholesterol
IT1255241B (en) * 1992-07-22 1995-10-20 Simos Contos BILIARY ACID DERIVATIVE AND ITS USE IN THERAPY
EP1189922A4 (en) * 1999-04-30 2002-08-14 Arch Dev Corp STEROID DERIVATIVES
ES2296928T3 (en) * 2001-05-03 2008-05-01 The University Of Chicago HEPATIC X RECEPTORS.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
EP0562849A2 (en) * 1992-03-27 1993-09-29 Eli Lilly And Company Steroid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCH. BIOCHEM. BIOPHYS., vol. 98, 1962, pages 305 - 311 *
DATABASE CAPLUS [online] WHITEHOUSE M. ET AL.: "Catabolism in vitro of cholesterol: some comparative aspects", XP002963337, accession no. STN Database accession no. 1962:464382 *
See also references of EP1450816A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
TW200300078A (en) 2003-05-16
WO2003039480A2 (en) 2003-05-15
JP2005508368A (en) 2005-03-31
EP1450816A2 (en) 2004-09-01
CA2466033A1 (en) 2003-05-15
EP1450816A4 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2003039480A3 (en) Method of treating disorder related to high cholesterol concentration
BR0114576A (en) Compound, pharmaceutical composition, use of a compound, method of treating a disease state and process for preparing a compound
DE69512797D1 (en) Prostaglandin-synthase hemmer
WO2001052796A3 (en) Methods of using a beverage composition for treating dental erosion
BR0316375A (en) Diazinopyrimidines
NO20062292L (en) Procedure for treating transplant rejection
ATE410400T1 (en) METHOD FOR PRODUCING C13 ALCOHOL MIXTURES
MXPA03011681A (en) Methods of using soluble epoxide hydrolase inhibitors.
DE60024830D1 (en) METHOD FOR PRODUCING HETEROARYL SUBSTITUTED UREA BONDING
MXPA03009840A (en) Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments.
WO2005030120A3 (en) Antiangiogenic agents
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
WO2003009803A3 (en) Method of improving cognitive function
ATE250077T1 (en) STEROID SULFATASE INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF
ATE430572T1 (en) USE OF SPONGOSIN (2-METHOXYADENOSINE) FOR THE TREATMENT OF PAIN, ESPECIALLY HYPERALGESIA
AU1185801A (en) Novel compounds
AU2003300385A1 (en) Anticancer compounds
WO2004024064A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
DE60202203D1 (en) NEW METHOD FOR THE PRODUCTION OF OXABISPIDINES
EA200600100A1 (en) DERIVATIVES NICOTINAMIDA USEFUL AS PDE4 INHIBITORS
WO2002014313A3 (en) Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments
CA2421990A1 (en) .beta.-thioamino acids
BR0312470A (en) Compound, use thereof, pharmaceutical composition, method of treating and / or preventing cancer, and process for preparing the compound
DE602004009664D1 (en) Diclazuril-containing antiperspirants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2466033

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003541772

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002356919

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002802882

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802882

Country of ref document: EP